Référentiel des médicaments
Danicopan
Danicopan is a medicine in the class miscellaneous.
- Classe médicamenteuse: Miscellaneous
Dernière mise à jour Sources: US FDA label
Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.
Le contenu clinique de cette page n'est disponible qu'en anglais.
L'essentiel
- Classe médicamenteuse
- Miscellaneous
- Code ATC
- L04AJ09
- Formes courantes
- comprimé
- Dosages courants
- 100 mg
- Interactions connues
- 97 (Modérée: 68 · Mineure: 29)
- Noms commerciaux
- 2
- Pays et marchés
- 2
Mécanisme d'action
Danicopan reversibly binds complement Factor D and selectively inhibits the alternative complement pathway. It prevents cleavage of Factor B and formation of C3 convertase (C3bBb), thereby controlling C3 fragment-mediated extravascular hemolysis in PNH.
Posologie adulte habituelle (résumé de la notice)
Extravascular hemolysis in PNH (add-on to ravulizumab or eculizumab): starting dose 150 mg orally three times a day, with or without food; may increase to 200 mg three times a day
Grossesse et allaitement
- Grossesse
- Unknown No human data. Use may be considered after risk-benefit assessment; untreated PNH carries maternal and fetal risks. No adverse developmental effects in rabbits or rats.
- Allaitement
- Unsafe No human milk data; present in animal milk. Advise not to breastfeed during treatment and for 3 days after the last dose.
Effets indésirables signalés
- Headache
- Vomiting
- Pyrexia
- Increased alanine aminotransferase
- Hypertension
- Pain in extremity
Mises en garde encadrées
- Complement inhibitor that increases the risk of serious, life-threatening or fatal infections with encapsulated bacteria (Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type B). Vaccinate against N. meningitidis and S. pneumoniae at least 2 weeks before the first dose unless delaying therapy is riskier, and follow current ACIP recommendations. Risk persists despite vaccination. Monitor for early signs of infection and evaluate immediately. Available only through the VOYDEYA REMS.
Contre-indications
- Initiation in patients with unresolved serious infection caused by encapsulated bacteria (Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type B)
Précautions particulières
- Serious encapsulated bacterial infections can occur in vaccinated and unvaccinated patients; if urgent therapy is needed in patients not up to date on vaccines, give antibacterial prophylaxis and vaccinate as soon as possible.
- Hepatic enzyme elevations (ALT) occurred; assess liver enzymes before and periodically during treatment.
- After discontinuation, monitor closely for at least 2 weeks for signs of hemolysis; continue background ravulizumab or eculizumab.
Informez votre pharmacien ou votre médecin en cas de grossesse ou d'allaitement, de maladie rénale ou hépatique, d'allergies, ainsi que de tout autre médicament ou complément que vous prenez.
Principales interactions (97)
- Amiodarone + Danicopan Moderate
- Apixaban + Danicopan Moderate
- Atorvastatin + Danicopan Moderate
- Brentuximab + Danicopan Moderate
- Carvedilol + Danicopan Moderate
- Cladribine + Danicopan Moderate
- Colchicine + Danicopan Moderate
- Crizotinib + Danicopan Moderate
- Cyclosporin + Danicopan Moderate
- Dabigatran etexilate + Danicopan Moderate
Réservé aux membres Pro+
Débloquer la page complète
Créez un compte et lancez un essai Pro+ pour ouvrir la monographie complète de Danicopan : posologie, grossesse et allaitement, effets indésirables, mises en garde et toutes les interactions.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Essayez Pro+ gratuitement pendant 14 jours sur le web. Sans carte.
Questions fréquentes
What is Danicopan used for?
Danicopan is a medicine in the class miscellaneous.
What side effects have been reported with Danicopan?
Headache, Vomiting, Pyrexia, Increased alanine aminotransferase, Hypertension, Pain in extremity. Serious warning: Complement inhibitor that increases the risk of serious, life-threatening or fatal infections with encapsulated bacteria (Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type B).
Can Danicopan be taken in pregnancy or while breastfeeding?
Pregnancy: Unknown. No human data. Use may be considered after risk-benefit assessment; untreated PNH carries maternal and fetal risks. No adverse developmental effects in rabbits or rats. Breastfeeding: Unsafe. No human milk data; present in animal milk. Advise not to breastfeed during treatment and for 3 days after the last dose.
What does Danicopan interact with?
MediHelp lists 97 known interactions for Danicopan. Moderate: 68 · Minor: 29. The most serious include Amiodarone, Apixaban, Atorvastatin.
Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp
Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.
